Pharmaceuticals
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system * Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed" LEVERKUSEN, Germany, July 26, 2021 /PRNewswire/ -- WuXi Biologics (...
2021-07-26 18:00
4515
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-07-26 08:00
7603
GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices
ATLANTA, July 23, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron® brachytherapy afterloader systems, including service agreements. The cancer treatment devices will allow GenesisCare to contin...
2021-07-23 21:02
9392
Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand
AMSTERDAM, Netherlands and LOUISVILLE, Ky., July 23, 2021 /PRNewswire/ -- NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and US WorldMeds (USWM), aKentucky-based specialty pharmaceutical company, today announced an exclusive licensing agreement by which Norgine will r...
2021-07-23 16:00
2218
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IN...
2021-07-22 21:50
10473
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high...
2021-07-22 13:00
4074
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
SHANGHAI and HONG KONG, July 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-07-22 09:27
3358
Joysbio's COVID-19 RAPID tests detect NEW SARS-COV-2 variants
TIANJIN, China, July 22, 2021 /PRNewswire/ -- Joysbio, one of the world's leading manufacturers of lateral flow rapid test kits, has proven that their SARS-CoV-2 (COVID-19) antigen tests can detect new variants, including the Delta variant that's sweeping the world. With over 100 million tests so...
2021-07-22 08:37
3740
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma
HANGZHOU, China and SHAOXING, China, July 22, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients w...
2021-07-22 08:30
3883
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order ...
2021-07-21 22:00
12276
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy
* Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND * Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ -- Sams...
2021-07-20 20:00
2187
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China
SHANGHAI, July 20, 2021 /PRNewswire/ -- Everest Medicines
2021-07-20 18:42
6213
Juventas Cell Therapy Ltd. Closes Series C Financing to Advance the "Rapid Commercialization and Internationalization" Development Strategy
TIANJIN, China, July 20, 2021 /PRNewswire/ -- Juventas Cell Therapy Ltd., a Chinese biopharmaceutical company announced the close of a $60 million+ Series C financing led by CICC Capital and Oceanpine Capital. The co-investors include Delian Capital and existing investors such as Jiadao Private C...
2021-07-20 10:47
2218
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcomes
The company employs real-world data and evidence to accelerate research through targeted site and patient recruitment strategies SANTA CLARA, Calif., July 20, 2021 /PRNewswire/ -- Based on its recent analysis of the global clinical research organization (CRO) market,Frost & Sullivan recognizes l...
2021-07-20 01:47
2244
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstratedpotent inhibition of Beta and Gamma variant...
2021-07-19 19:21
18115
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax
SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has entered into a Cooperative ...
2021-07-19 18:41
4500
Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients
* The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies * TALENT is the world's first phase III clinical trial of the new long-acting HIV...
2021-07-19 16:23
3653
YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from the UAE
BEIJING, July 19, 2021 /PRNewswire/ -- YishengBio Co., Ltd ("YishengBio") today announced that it has received IND clearance for PIKA recombinant COVID-19 vaccine to conduct Phase I clinical trial from United Arab Emirates Ministry of Health & Prevention. PIKA recombinant COVID-19 vaccine is a PI...
2021-07-19 09:00
3623
Bioelectronica Announces Hypercell™ Expansion for Antibody Discovery, Closing of Oversubscribed Series A Financing, Powering Local Hiring Growth and Expansion of Facilities in Reno
RENO, Nev., July 19, 2021 /PRNewswire/ -- Bioelectronica® Corporation ("Bioelectronica") announced today that it has secured an undisclosed amount in its Series A financing round due to increased interest in Hypercell™, a new hardware tool that can be used to discover new antibodies using compute...
2021-07-19 08:59
3451
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
SUZHOU, China, July 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced thatParaguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emerg...
2021-07-16 14:41
37098
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 307 media titles]
2026-05-19 23:59
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 289 media titles]
2026-05-18 15:30
AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
8023
